M&A
Should this deal happen, and what is it worth? M&A cases test whether you can value a target, judge synergies honestly, and weigh the soft factors that sink most real deals. This is the overview; valuation, due diligence, and the private-equity lens each get their own page.
An M&A case looks intimidating — valuation, synergies, due diligence, integration — but it collapses to one question: is the net benefit of this deal positive? Value created, plus synergies, minus the price and the cost to integrate — and then the soft checks that quietly kill most real deals. Get that equation framed and the rest is just filling in the terms.
TL;DR · Key Takeaways
Key Takeaways
- You will frame every M&A case as one question — is net benefit positive? — where value created plus synergies must exceed price plus integration cost, and the soft factors must not veto it.
- You will identify the buyer first: a strategic buyer chases synergies and fit; a financial buyer (PE) chases returns and an exit — and the lens changes what you analyse.
- You will value the target standalone before adding synergies, and size synergies conservatively because revenue synergies are the most overestimated number in deals.
- You will treat acquirer fit (cultural, organizational, strategic) and external risk as real veto factors, since most failed deals fail on the soft side, not the spreadsheet.
- You will follow the thread into Value & Synergies, Due Diligence, and the Private Equity lens as the specific case demands, rather than treating M&A as one undifferentiated topic.
Mergers and acquisitions are the deep-dive on inorganic growth — when a company (or an investor) grows by buying rather than building. These cases reward structure and honesty: a clear valuation, conservative synergies, and the discipline to flag when culture, integration, or risk should override an attractive spreadsheet. This page frames the whole decision; the linked pages go deep on each piece.
This is a multi-part framework
M&A is broad, so it is split across pages. This overview covers the net-benefit decision and the buyer's lens. Value & Synergies goes deep on what the combination is worth; Due Diligence covers the investigate-before-you-buy process; and Private Equity reframes everything for a financial buyer focused on returns and exit. Start here, then follow the thread that fits your case.
The net-benefit tree
Frame every deal as a single question: is the net benefit positive? It splits into a financial half (does the math work?) and a non-financial half (should we, beyond the math?). Both must clear — a deal that pencils out can still fail on culture or risk.
Who is buying — and why it changes everything
Before structuring, ask one question that reframes the entire case: is this a strategic buyer or a financial buyer? A company buying a company chases synergies and fit; a PE fund buying to sell later chases returns and an exit. They share the valuation and due-diligence toolkit, but what creates value — and therefore what you analyse — is different.
Name the buyer first
This single question saves you from the most common M&A misstep: running a synergy analysis for a PE fund, or a returns-and-exit analysis for a strategic acquirer. The Private Equity page takes the financial-buyer view in full; everything else in this section assumes a strategic buyer unless stated.
Navigating it live
The live path is disciplined: clarify the buyer, value the target on its own, add synergies conservatively, then test that total against the price and integration cost — and only then weigh the soft factors. Value before price, math before fit, but never skip fit.
Worked mini-case
Watch the net-benefit frame in action — the candidate refuses to debate the headline price first, values the target standalone, sizes synergies honestly, and lets the soft factors carry real weight.
A packaged-foods acquisition
Our client is a large Indian FMCG company. A regional health-snacks brand is for sale at ₹400cr, and our client is considering buying it. Should they?
I'll frame this as: is the net benefit positive? That is the standalone value of the snacks brand, plus synergies our client can create, minus the ₹400cr price and the cost to integrate — and then whether the non-financial factors support it. First, is this a strategic buyer? It sounds like an FMCG company buying for strategic reasons, not a fund, so I'll lead with synergies and fit rather than exit.
Correct, strategic buyer. Where do you go?
I'd value the brand standalone first — the present value of its own cash flows at current trajectory. Then synergies, and here our client has a real one: their distribution network. A regional brand sold at ₹400cr is probably distribution-constrained; pushing it through a national FMCG network could materially lift volume. That is a revenue synergy. There may be cost synergies too — shared manufacturing, procurement scale, combined SG&A. I'd size the revenue synergy carefully, because that is usually the bigger and the more overestimated number.
Say the brand is worth ₹350cr standalone and you estimate ₹120cr of synergies. The price is ₹400cr. Verdict?
Standalone ₹350cr plus ₹120cr synergies is ₹470cr of value, against a ₹400cr price — so on the math there is roughly ₹70cr of positive net benefit before integration cost. I'd want the integration cost estimate, because if it runs ₹40-50cr the margin gets thin. But the bigger flag is the soft side: a health-snacks brand often has a founder-led, premium culture that can clash with a large FMCG operating model. If integration crushes what made the brand work, the ₹120cr synergy evaporates. So my answer is a conditional yes — the deal creates value if they can protect the brand's identity and keep integration cost in check, and I'd cap the price near ₹400cr rather than chase it higher.
The candidate framed net benefit explicitly, valued standalone before synergies, identified the real revenue synergy (distribution) while flagging it as the overestimated number, and let culture and integration carry veto weight rather than treating the deal as a pure math problem.
Value standalone first, size synergies conservatively, and let the soft factors genuinely count.
Synergies are where deals overpay
Revenue synergies are the most overestimated number in M&A — they assume the combined business sells more than the two did apart, which often does not materialise. Size them conservatively, separate them from standalone value, and never let the synergy story justify a price the standalone value cannot. When in doubt, discount the synergy and see if the deal still clears.